Variable
|
TTP
|
OS
|
---|
HT vs. MCT
|
HT vs. MCT
|
---|
Median (months)
|
13 vs. 8
|
43 vs. 37
|
HR by unadjusted Cox regression
|
0.64
|
0.82
|
95% CI
|
0.44–0.91
|
0.50–1.32
|
Log-rank P value
|
0.011
|
0.400
|
HR by adjusteda Cox regression
|
0.65
|
0.83
|
95% CI
|
0.43–0.93
|
0.49–1.37
|
P value
|
0.018
|
0.450
|
-
HR hazard ratio, CI confidence interval, HT hormonal therapy, MCT maintenance capecitabine monotherapy
-
aAdjusted to menopausal status, Karnofsky performance status, number of metastasis sites, interval of disease-free survival, visceral disease, and response to FCCT, which were all predefined in the study protocol